Literature DB >> 10147930

Depletion of natural antibodies in non-human primates--a step towards successful discordant xenografting in humans.

D K Cooper1.   

Abstract

There is evidence to suggest that long-term survival of discordant xenografts may be possible if the organ is transplanted at a time when the host natural anti-species (xenoreactive) antibodies are temporarily absent or otherwise inhibited from reacting with the donor antigens. There is also evidence that the target antigens on pig organs may be carbohydrate structures, as are the human A and B blood group antigens. The intravenous infusion of synthetic A or B trisaccharides in hyperimmunized baboons, coupled with pharmacologic immunosuppression, has prolonged ABO-incompatible cardiac allograft survival from a mean of 19 minutes to several days, and even to several weeks in one animal. The nature of the carbohydrate structures of the pig antigens against which human xenoreactive antibodies are directed has been investigated. Two of the most important of these would appear to be alpha galactosyl structures, referred to as linear B. If the central role of these carbohydrates can be confirmed, then it may be possible to adsorb out or inhibit human anti-pig antibodies in the same way as anti-A and anti-B antibodies. It may then be possible to offer organ transplantation to all suitable recipients under elective conditions without the restriction of donor availability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 10147930

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  17 in total

1.  A brief history of cross-species organ transplantation.

Authors:  David K C Cooper
Journal:  Proc (Bayl Univ Med Cent)       Date:  2012-01

Review 2.  Xenotransplantation--the future of corneal transplantation?

Authors:  Hidetaka Hara; David K C Cooper
Journal:  Cornea       Date:  2011-04       Impact factor: 2.651

3.  Identification of the tetraspanin CD82 as a new barrier to xenotransplantation.

Authors:  Soad M Saleh; Ranjit S Parhar; Reem S Al-Hejailan; Razan H Bakheet; Hala S Khaleel; Hanif G Khalak; Anason S Halees; Marya Z Zaidi; Brian F Meyer; Gisella P Yung; Jörg D Seebach; Walter Conca; Khalid S Khabar; Kate S Collison; Futwan A Al-Mohanna
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

4.  The effect of Gal expression on pig cells on the human T-cell xenoresponse.

Authors:  Tyler Wilhite; Corin Ezzelarab; Hidetaka Hara; Cassandra Long; David Ayares; David K C Cooper; Mohamed Ezzelarab
Journal:  Xenotransplantation       Date:  2012 Jan-Feb       Impact factor: 3.907

Review 5.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

6.  Anti-gal antibodies in α1,3-galactosyltransferase gene-knockout pigs.

Authors:  Jason Fang; Anneke Walters; Hidetaka Hara; Cassandra Long; Peter Yeh; David Ayares; David K C Cooper; John Bianchi
Journal:  Xenotransplantation       Date:  2012-09-13       Impact factor: 3.907

Review 7.  Overcoming the barriers to xenotransplantation: prospects for the future.

Authors:  Burcin Ekser; David K C Cooper
Journal:  Expert Rev Clin Immunol       Date:  2010-03       Impact factor: 4.473

8.  Frankenswine, or bringing home the bacon: How close are we to clinical trials in xenotransplantation?

Authors:  David Kc Cooper
Journal:  Organogenesis       Date:  2008-01       Impact factor: 2.500

Review 9.  Modifying the sugar icing on the transplantation cake.

Authors:  David K C Cooper
Journal:  Glycobiology       Date:  2016-03-01       Impact factor: 4.313

Review 10.  Skin xenotransplantation: Historical review and clinical potential.

Authors:  Takayuki Yamamoto; Hayato Iwase; Timothy W King; Hidetaka Hara; David K C Cooper
Journal:  Burns       Date:  2018-03-27       Impact factor: 2.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.